Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ENT-06
- Development stage
- Preclinical
- Lead developer
- Enterin
- Modality
- Small Molecules
01
Overview
ENT-06 is an investigational small molecule therapeutic currently in preclinical development by Enterin for the treatment of neurodegenerative diseases. Enterin's research platform is centered on the "gut-brain axis," specifically investigating how the enteric nervous system influences central nervous system health and disease progression. While the specific molecular target and mechanism of action for ENT-06 have not been publicly detailed, the company's broader portfolio focuses on modulating protein aggregation (such as alpha-synuclein) and metabolic signaling pathways. ENT-06 represents an expansion of Enterin's pipeline into broader neurodegenerative indications beyond their lead programs in Parkinson's disease and dementia.
Beyond the preview
Go deeper on ENT-06.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ENT-06.